T Cell News and Research

Latest T Cell News and Research

Kinase inhibitors can arrest growth of cancer cells at early stages

Kinase inhibitors can arrest growth of cancer cells at early stages

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals raises funds for the development of romidepsin

MicroRNAs in saliva could aid in the detection of oral cancer

MicroRNAs in saliva could aid in the detection of oral cancer

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

Cord Blood America announces retirement of $1.6 million in debt since July 2009

Cord Blood America announces retirement of $1.6 million in debt since July 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

OriGene Technologies releases recombinant proteins purified from HEK293 cells

OriGene Technologies releases recombinant proteins purified from HEK293 cells

Combined therapy for acute leukemia shows promising results

Combined therapy for acute leukemia shows promising results

University of Southampton develops a microfluidic single-cell impedance cytometer for blood cell analysis

University of Southampton develops a microfluidic single-cell impedance cytometer for blood cell analysis

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Scientists cultivate multiple types of retina cells from human stem cells

Scientists cultivate multiple types of retina cells from human stem cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.